The average time needed to set up commercial clinical trials in the UK has fallen by 35%, according to new government figures, marking progress in efforts to attract medical research investment and accelerate the start of studies involving patients.
The Department of Health and Social Care said on 21 October that average set-up time reached 100 days in the three months to March 2026, compared with 153 days in the same period a year earlier. All 24 commercial studies in the latest sample were set up within 150 days, exceeding the government’s target for 95% to meet that threshold.
These figures measure the preparation needed before a study can proceed. They do not describe the time required to recruit every patient, collect evidence, complete follow-up or obtain approval for a resulting medicine. Those later stages may take years depending on the disease and trial design.
Speeding up the initial process is still commercially important. Pharmaceutical and biotechnology sponsors consider whether hospitals, ethics systems, regulators and contractual processes can support a study on schedule. Long delays can add operating costs, weaken recruitment plans and make another jurisdiction more attractive.
In its announcement, the government separately reported that all studies receiving combined medicines regulator and research ethics approval during September 2026 obtained it within 60 days. This measure is not equivalent to the average commercial trial set-up period, which involves additional practical preparation before research sites can begin work.
The government highlighted the BEATRIX study, which explores a vaccine against group B streptococcus infection, and a Moderna study that recruited 2,500 volunteers in nine weeks. Those examples illustrate different operational measures: authorising and setting up research on one hand, and finding participants on the other.
Successful trials need coordination among sponsors, hospitals, research nurses, specialists and administrators. Sites may need to confirm staffing, access to equipment, data handling arrangements and contractual responsibilities before patients can be recruited safely. More efficient administration can reduce wasted time without changing scientific standards.
Patient safety and ethical oversight remain essential. Faster decisions are useful only where consent, monitoring and protocol requirements are maintained. A trial that begins earlier does not automatically establish that the treatment being studied works, and the results may still fail to support an approval application.
The UK competes with other research markets on patient access, clinical expertise and the availability of specialist facilities as well as speed. Sponsors will examine whether the improved set-up performance is sustained across more studies and a wider variety of clinical areas, not only a three-month group of 24 commercial trials.
For the life sciences industry, predictability is almost as important as the average. Companies planning international studies must coordinate sites across multiple countries. An unusually delayed approval or contract can affect the timetable for the wider programme even if other sites are ready to start.
The Life Sciences Sector Plan links research performance with investment, manufacturing and commercialisation. Officials said the first year had attracted more than £3bn in public-private investment, although those commitments may have different timelines and should not be confused with a single cash payment.
The latest trial sample is relatively small, which makes the consistency of later quarterly results important. A single difficult-to-launch study can influence average set-up times materially when there are only 24 observations. Future reporting should also examine whether faster approvals hold for studies requiring multiple hospital sites or complex arrangements. Transparent definitions and comparable measurement periods will help sponsors assess whether the government’s progress reflects a lasting system improvement rather than temporary variation in the mix of studies.
Faster set-up could improve Britain’s appeal to companies deciding where to allocate clinical research budgets. Sustained performance and independently measurable outcomes will be needed before the government can establish whether the change results in a larger share of international studies.
You must be logged in to post a comment.